Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)
(Incorporated in Bermuda with limited liability)
(Stock Code: 673)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2020

Reference is made to the annual report of China Health Group Limited (the "**Company**" together with its subsidiaries the "**Group**") for the year ended 31 March 2020 (the "**2020 Annual Report**"). Terms used herein shall have the same meanings as defined in the 2020 Annual Report unless otherwise stated.

The board of directors (the "**Board**") of the Company wishes to provide the following additional information in relation to Share Option Scheme as disclosed in the Report of the Directors and Note 35 to the consolidated financial statements in the 2020 Annual Report.

SHARE OPTION SCHEME

The Company operated a share option scheme which was expired on 7 April 2012 and a new share option scheme (the "**New Scheme**") was approved by the shareholders of the Company on 28 August 2012. The purpose of the both share option schemes is to reward the eligible participants of the Group who have contributed or are expected to contribute the Group and to encourage them to work towards enhancing the value of the Company and its shares for the benefit of the Company and its shareholders as a whole. The New Scheme shall be valid and effective for a period of ten years ending on 28 August 2022.

The total number of securities available for issue under the share option scheme(s) of the Company as at 31 March 2020 was 543,294,763 shares (including share options for 133,900,000 shares that have been granted but not yet lapsed or exercised) which represented 13.12% of the ordinary shares of the company in issue at 31 March 2020.

The Company granted 321,994,763 share options during the year. Out of which, 218,994,763 were granted to CHG Victory Limited ("**CHGV**"), a company whose shares are held by a trustee on trust for the benefit of the employees and consultants of the Group, and CHGV had accepted the Options. Since none of the Options had been allocated to the Beneficiaries or exercised, and as the identities of the Beneficiaries have not been specified in strict compliance with the requirements under Rule 17.01(1) of the Listing Rules, the Company and CHGV mutually agreed that the aforesaid 218,994,763 Options were cancelled with effect from 26 July 2019 in accordance with the terms of the Share Option Scheme.

The Board confirms that the above supplemental information does not affect other information contained in the 2020 Annual Report. Save as disclosed above, the contents of the 2020 Annual Report remain unchanged.

By Order of the Board
China Health Group Limited
Zhang Fan
Chairman and Executive Director

Hong Kong, 27 July 2021

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho and Mr. Wang Jingming; two non-executive Directors, namely, Mr. Xing Yong and Mr. Huang Lianhai; and four independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua, Mr. Lai Liangquan and Ms. Meng Junfeng.